Humacyte (NASDAQ:HUMA) Stock Rating Reaffirmed by Benchmark

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating reaffirmed by research analysts at Benchmark in a report issued on Tuesday, Benzinga reports. They currently have a $15.00 price objective on the stock. Benchmark’s target price suggests a potential upside of 164.55% from the company’s previous close.

A number of other equities research analysts also recently issued reports on HUMA. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $7.00 price objective on shares of Humacyte in a research report on Monday, April 1st. Piper Sandler reaffirmed a “neutral” rating and issued a $4.00 price objective on shares of Humacyte in a research report on Tuesday, March 26th.

Humacyte Price Performance

Shares of NASDAQ HUMA opened at $5.67 on Tuesday. The firm’s 50-day moving average price is $5.98 and its 200-day moving average price is $4.23. Humacyte has a 1-year low of $1.96 and a 1-year high of $9.97. The firm has a market capitalization of $675.18 million, a P/E ratio of -5.67 and a beta of 1.52. The company has a current ratio of 8.37, a quick ratio of 8.37 and a debt-to-equity ratio of 0.61.

Humacyte (NASDAQ:HUMA) last posted its earnings results on Friday, May 10th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Equities research analysts anticipate that Humacyte will post -0.95 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Brady W. Dougan sold 271,518 shares of the firm’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $7.30, for a total transaction of $1,982,081.40. Following the sale, the director now owns 4,559,140 shares in the company, valued at approximately $33,281,722. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Humacyte news, Director Gordon M. Binder bought 50,000 shares of Humacyte stock in a transaction that occurred on Wednesday, May 15th. The shares were bought at an average price of $6.78 per share, with a total value of $339,000.00. Following the acquisition, the director now owns 160,000 shares in the company, valued at $1,084,800. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Brady W. Dougan sold 271,518 shares of the stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $7.30, for a total transaction of $1,982,081.40. Following the transaction, the director now directly owns 4,559,140 shares in the company, valued at approximately $33,281,722. The disclosure for this sale can be found here. In the last three months, insiders have bought 54,412 shares of company stock worth $369,107 and have sold 1,628,820 shares worth $12,464,121. Corporate insiders own 23.10% of the company’s stock.

Institutional Investors Weigh In On Humacyte

A number of large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of Humacyte by 28.7% in the 1st quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock worth $12,501,000 after purchasing an additional 896,415 shares during the period. GSA Capital Partners LLP lifted its position in shares of Humacyte by 139.5% in the 3rd quarter. GSA Capital Partners LLP now owns 355,918 shares of the company’s stock worth $1,043,000 after purchasing an additional 207,333 shares during the period. Private Advisor Group LLC lifted its position in shares of Humacyte by 232.7% in the 1st quarter. Private Advisor Group LLC now owns 317,624 shares of the company’s stock worth $988,000 after purchasing an additional 222,144 shares during the period. Capstone Investment Advisors LLC purchased a new stake in shares of Humacyte in the 1st quarter worth about $972,000. Finally, United Asset Strategies Inc. lifted its position in shares of Humacyte by 53.9% in the 4th quarter. United Asset Strategies Inc. now owns 221,308 shares of the company’s stock worth $629,000 after purchasing an additional 77,500 shares during the period. Institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.